PMID- 8567851
OWN - NLM
STAT- MEDLINE
DCOM- 19960307
LR  - 20190512
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 10
IP  - 8
DP  - 1995 Aug
TI  - Immunolocalization of transforming growth factor-beta 1 and transforming growth 
      factor-beta 2 in the mouse ovary during gonadotrophin-induced follicular 
      maturation.
PG  - 2115-9
AB  - An immunohistochemical approach was utilized to evaluate the cellular 
      distribution of transforming growth factor-beta 1 (TGF beta 1) and transforming 
      growth factor beta 2 (TGF beta 2) at different stages of follicle development in 
      the prepubertal mouse ovary under the following conditions: (i) after pregnant 
      mare's serum gonadotrophin (PMSG) treatment; (ii) after PMSG and human chorionic 
      gonadotrophin (HCG) treatment; (iii) after PMSG and HCG treatment plus mating. In 
      the immature ovary, TGF beta 1 and TGF beta 2 immunoreactivities are localized in 
      theca and granulosa cells and in oocytes. After PMSG treatment, TGF beta 1 and 
      TGF beta 2 immunoreactivities are localized in granulosa cells; in addition, TGF 
      beta 2 staining is noted in the matrix surrounding antral cells. Staining for 
      both TGR beta 1 and TGF beta 2 drops in the theca but persists in the oocyte. 
      PMSG plus HCG treatment results in a significant increase in TGF beta 1 and TGF 
      beta 2 immunoreactivity in the theca and in the maintenance of TGF beta 1 
      staining in both basal granulosa cells and cumulus cells whereas TGF beta 2 
      immunoreactivity is essentially localized in the matrix surrounding cumulus 
      cells. Staining for TGF beta 1 and TGF beta 2 persists in the oocyte. Following 
      PMSG plus HCG treatment and mating, TGF beta 1 immunoreactivity is localized in 
      the luteal cells of corpora lutea and TGF beta 2 shows a similar localization 
      pattern. This study provides evidence that TGF beta 1 and TGF beta 2 peptides are 
      expressed in specific cell types during induced follicular maturation in the 
      mouse ovary.
FAU - Ghiglieri, C
AU  - Ghiglieri C
AD  - INSERM U407, Centre Hospitalier Lyon-Sud, Pierre-Benite, France.
FAU - Khatchadourian, C
AU  - Khatchadourian C
FAU - Tabone, E
AU  - Tabone E
FAU - Hendrick, J C
AU  - Hendrick JC
FAU - Benahmed, M
AU  - Benahmed M
FAU - Menezo, Y
AU  - Menezo Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 0 (Chorionic Gonadotropin)
RN  - 0 (Gonadotropins, Equine)
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
MH  - Animals
MH  - Chorionic Gonadotropin/pharmacology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follicular Phase/*metabolism
MH  - Gonadotropins, Equine/*pharmacology
MH  - Humans
MH  - Immunohistochemistry
MH  - Mice
MH  - Ovarian Follicle/*drug effects/growth & development
MH  - Ovary/chemistry/*drug effects
MH  - Sexual Behavior, Animal/physiology
MH  - Sexual Maturation/*physiology
MH  - Transforming Growth Factor beta/*analysis
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.humrep.a136245 [doi]
PST - ppublish
SO  - Hum Reprod. 1995 Aug;10(8):2115-9. doi: 10.1093/oxfordjournals.humrep.a136245.